Compare ADMA Biologics Inc (ADMA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Trip.com Group Ltd — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Trip.com Group Ltd trades at $41.45 (market cap $25.65B). The key difference: Trip.com Group Ltd is far larger — about 12× ADMA Biologics Inc's market cap, and Trip.com Group Ltd pays a 0.57% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TCOM | |
|---|---|---|
Market Cap | $2.13B | $25.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $78.96 |
52-Week Low | $7.60 | $39.84 |
Enterprise Value | $2.20B | $18.35B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Trip.com Group (TCOM) trades at $40.81, down 0.46% on the day, near its 52-week low. The stock shows bearish technical signals with oversold RSI readings. Fundamentally, TCOM reported Q1 2026 revenue growth of 17% year-over-year but missed EPS estimates, with Q2 revenue guidance of 3%-8% growth disappointing investors. The company maintains strong profitability with a 48.65% net margin and attractive valuation multiples, including a P/E of 6.16. Recent news highlights regulatory scrutiny and a significant stock selloff following earnings.
The outlook for TCOM is mixed. Strong cash flow, dominant market position in Chinese travel, and low valuations support upside potential toward the $56.72 analyst target. However, near-term risks include regulatory investigations, margin pressure from cost growth, and bearish technical trends. Investors should weigh solid fundamentals against heightened sentiment risks and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
